Fol. Biol. 2007, 53, 216-219
https://doi.org/10.14712/fb2007053060216
Multiplex Analysis of Cytokines Involved in Tumour Growth and Spontaneous Regression in a Rat Sarcoma Model
References
1. , T., Tickle, S., Wasan, R., Docherty, A., Isenberg, D., Waxman, J. (1994) Serum metalloproteinases and their inhibitors: markers for malignant potential. Br. J. Cancer 70, 506-512.
<https://doi.org/10.1038/bjc.1994.336>
2. , M. J., Clayman, G. L. (2001) Chemokines in cancer. Expert Rev. Mol. Med. 18, 1-18.
<https://doi.org/10.1017/S1462399401003301>
3. , Y., Yoshiji, H., Kuriyama, S., Yoshii, J., Noguchi, R., Tsujinoue, H., Yanase, K., Namisaki, T., Imazu R., Masaki, T., Fukui, H. (2003) Tissue inhibitor of metalloproteinase-1 (TIMP-1) inhibits tumour growth and angiogenesis in the TIMP-1 transgenic mouse model. Int. J. Cancer 105, 340-346.
<https://doi.org/10.1002/ijc.11094>
4. , Y., Goldberg, I. D., Shi, Y. E. (2002) Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 21, 2245-2252.
<https://doi.org/10.1038/sj.onc.1205291>
5. , B., Smith, J. B., Freeman, G. L. (2001) Ischemia-reperfusion of rat myocardium activates nuclear factor-κB and induces neutrophil infiltration via lipopolysaccharide-induced CXC chemokine. Circulation 103, 2296-2302.
<https://doi.org/10.1161/01.CIR.103.18.2296>
6. , B. V., Karikehalli, S., Haholu, A., Sheehan, C. E., Azumi, N., Ross, J. S. (2001) Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin. Cancer Res. 7, 3113-3119.
7. , R. (1994) Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinase-1. J. Natl. Cancer Inst. 86, 299-304.
<https://doi.org/10.1093/jnci/86.4.299>
8. , L., Dušek, L., Šimíčková, M., Kocák, I., Vagundová, M., Žaloudík, J., Kovařík, J. (2002) Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response. Neoplasma 49, 159-166.
9. , H., Patel, V., Wang, H., Edmunds, R. K., Gutkind, J. S., Yeudall W. A. (2006) Down-regulation of CXCL5 inhibits squamous carcinogenesis. Cancer Res. 66, 4279-4284.
<https://doi.org/10.1158/0008-5472.CAN-05-4398>
10. , A., Málek, O., Pokorná, E., Strnádel, J., Hradecký, J., Horák, V. (2005) Immune characterization of the Lewis rats inoculated with K2 sarcoma cell line and newly derived R5-28 malignant cells. Folia Biol. (Praha) 51, 159-165.
11. , M., Tosato, G. (2006) Tumour cell populations differ in angiogenic activity: A model system for spontaneous angiogenic switch can tell us why. J. Natl. Cancer Inst. 98, 294-295.
<https://doi.org/10.1093/jnci/djj099>
12. , M., Schaider, H., Miller, T. H., Herlyn, M. (2001) Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumour formation in nontumourigenic melanoma cells. J. Immunol. 166, 483-6490.
<https://doi.org/10.4049/jimmunol.166.11.6483>
13. , J. E., Carbone, D. P. (2001) VEGF as a mediator of tumor associated immunodeficiency. Immunol. Res. 23, 263-272.
<https://doi.org/10.1385/IR:23:2-3:263>
14. , N., Yasutomi, M., Yamada, A., Iwasaki, H., Mayumi, M., Ohshima, Y. (2002) Monocyte chemoattractant protein-1 selectively inhibits the acquisition of CD40 ligand-dependent IL-12 producing capacity of monocyte-derived dendritic cells and modulates Th1 immune response. J. Immunol. 169, 4861-4866.
<https://doi.org/10.4049/jimmunol.169.9.4861>
15. , S., Hoehner, J. C. (1996) Neutrophin receptors, tumour progression and tumour maturation. Mol. Med. Today 2, 432-438.
<https://doi.org/10.1016/1357-4310(96)84847-7>
16. , A., Greco, S., Mariotta, S., Felici, L., Bronzetti, E., Cavazzana, A., Cardillo, G., Amenta, F., Bisetti, A., Barbolini, G. (2001) Neutrophins and neutrophin receptors in human lung cancer. Am. J. Respir. Cell Mol. Biol. 25, 439-446.
<https://doi.org/10.1165/ajrcmb.25.4.4470>
17. , M. R., Shurin, G. V., Lokshin, A., Yurkovetsky, Z. R., Gutkin, D. W., Chatta, G., Yhong, H., Han, B., Ferris, R. L. (2006) Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dentritic cells: friends or enemies? Cancer Metastasis Rev. 25, 333-356.
<https://doi.org/10.1007/s10555-006-9010-6>
18. , Y., Sato, H., Endo, Y., Okada, Y., Mai, M., Sasaki, T., Seiki, M. (1993) Tissue inhibitor of metalloproteinase 1 is a negative regulator of the metastatic ability of a human gastric cancer cell line, KKLS, in the chick embryo. Cancer Res. 53, 1397-1402.
19. Horssen, R., Ten Hagen, T. L. , Eggermont, A. M. (2006) TNF-α in cancer treatment: Molecular insights, antitumour effects and clinical utility. Oncologist 11, 397-408.
20. , A. P., Caux, C. H. (2002) Chemokines in cancer. Cytokine Growth Factor Rev. 13, 143-154.
<https://doi.org/10.1016/S1359-6101(01)00033-8>
21. , A., Haelens, A., Proost, P., Lenaerts, J. P., Conings, R., Opdenkker, G., Van Damme, J. (1996) Identification of mouse granulocyte chemotactic protein-2 from fibroblasts and epithelial cells. Functional comparison with natural KC and macrophage inflammatory protein-2. J. Immunol. 157, 1736-1743.
<https://doi.org/10.4049/jimmunol.157.4.1736>
22. , H., Harris, S. R., Raso, E., Gomez, D. E., Lindsay, C. K., Shibuya, M., Sinha, C. C., Thorgeirsson, U. P. (1998) Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinase-1 show enhanced vascular endothelial growth factor expression. Int. J. Cancer 75, 81-87.
<https://doi.org/10.1002/(SICI)1097-0215(19980105)75:1<81::AID-IJC13>3.0.CO;2-G>
